CRISPR Therapeutics AG — Director's Dealing 2024

May 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2024-05-23

Reporting Person: Bruno Julianne (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-23	Restricted Stock Units	$	A	20000	Acquired		Common Shares (20000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: This restricted stock unit award was granted on May 23, 2024 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 23, 2026.